Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 19/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17030566 | 0.88 | CFTR (0.42) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL350751 | 0.86 | CFTR (0.51) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL15679265 | 0.84 | CFTR (0.48) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL724752 | 0.84 | CFTR (0.51) | CFTR | |
| SCHEMBL13561360 | 0.84 | CFTR (0.56) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL19449871 | 0.84 | CFTR (0.47) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL21256244 | 0.84 | CFTR (0.50) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL12286746 | 0.82 | CFTR (0.47) | CFTR | |
| SCHEMBL16110568 | 0.82 | CFTR (0.48) | CFTR | |
| SCHEMBL19449903 | 0.80 | CFTR (0.53) | CFTRNR1I2ADORA3CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019018395-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-24 | — | — | WO | disclosed |
| US-20180153874-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180127398-A1 | SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-05-10 | — | — | US | disclosed |
| EP-2789606-B1 | Modulators of CFTR | VERTEX PHARMA (US) | 2017-11-15 | — | — | EP | disclosed |
| WO-2017175161-A1 | SOLID FORMS OF LUMACAFTOR, ITS SALTS AND PROCESSES THEREOF | DR. REDDY’S LABORATORIES LIMITED (IN) | 2017-10-12 | — | — | WO | disclosed |
| US-9776968-B2 | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170158676-A9 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-06-08 | — | — | US | disclosed |
| US-20160200712-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200684-A2 | Pharmaceutical Compositions for the Treatment of CFTR-Mediated Disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-07-14 | — | — | US | disclosed |
| US-9321725-B2 | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-04-26 | — | — | US | disclosed |
| US-8124781-B2 | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-28 | — | — | US | disclosed |
| WO-2011133953-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133956-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110257223-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110251253-A1 | SOLID FORMS OF (R)-1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL) CYCLOPROPANECARBOXAMIDE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110071206-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-24 | — | — | US | disclosed |
| US-20100036130-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-11 | — | — | US | disclosed |
| US-7645789-B2 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090176989-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257223-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, CLCN2, ABCB11 | CFTR 1/4885NR1I2 616/4885ADORA3 484/4885 |
| US-20180127398-A1 | SOLID FORMS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID | FIBP, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, BMX | CFTR 286/4885NR1I2 913/4885ADORA3 1761/4885 |
| US-20180153874-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | CFTR, ABCB11, ABCC5 | CFTR 1/4885NR1I2 1283/4885ADORA3 1102/4885 |
| US-20110071206-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | CFTR 1/4885NR1I2 491/4885ADORA3 192/4885 |
| US-20160200712-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | DDC, PCCA, KMO | CFTR 3920/4885NR1I2 4556/4885ADORA3 3375/4885 |
| US-20160200684-A2 | Pharmaceutical Compositions for the Treatment of CFTR-Mediated Disorders | CFTR, CLIC1, PKD2 | CFTR 1/4885NR1I2 1414/4885ADORA3 942/4885 |
| US-20090176989-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | DDC, PCCA, KMO | CFTR 3920/4885NR1I2 4556/4885ADORA3 3375/4885 |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | CFTR, ABCB1, ABCB11 | CFTR 1/4885NR1I2 791/4885ADORA3 94/4885 |
| US-20170158676-A9 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | DDC, PCCA, KMO | CFTR 3920/4885NR1I2 4556/4885ADORA3 3375/4885 |
| US-20100036130-A1 | PROCESSES FOR PRODUCING CYCLOALKYLCARBOXAMIDO-PYRIDINE BENZOIC ACIDS | DDC, PCCA, KMO | CFTR 3920/4885NR1I2 4556/4885ADORA3 3375/4885 |
| US-20110251253-A1 | SOLID FORMS OF (R)-1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL) CYCLOPROPANECARBOXAMIDE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, AFF1, FLNA | CFTR 1675/4885NR1I2 585/4885ADORA3 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.